Dr. Benjamin M. Heyman, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 263
Licensed in California since 2018, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Virginia School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
CA license A157684 (first issued 2018; current) -
Hematology & Oncology Physician
CA license A157684 (first issued 2018; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
Medical groups
- Regents of the University of California (2,089 clinicians)
- City of Hope Medical Foundation (982 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 263
- Services billed
- 970
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 250 | 151 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 111 | 46 |
| Established patient office or other outpatient visit, 30-39 minutes | 103 | 61 |
| Established patient office or other outpatient visit, 40-54 minutes | 91 | 31 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 52 | 51 |
| New patient office or other outpatient visit, 45-59 minutes | 25 | 25 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| Advance care planning, first 30 minutes | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Irvine, CA | 237 |
| Revlimid (lenalidomide) | 90 |
| Gabapentin Other prescribers in Irvine, CA | 69 |
| Prednisone Other prescribers in Irvine, CA | 63 |
| Eliquis (apixaban) Other prescribers in Irvine, CA | 62 |
| Omeprazole Other prescribers in Irvine, CA | 54 |
| Brukinsa (zanubrutinib) | 50 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Irvine, CA | 44 |
| Calquence (acalabrutinib maleate) | 43 |
| Entecavir | 41 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $7,379 in total to this clinician.
| Sobi, Inc | $4,235 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $2,815 |
| Cardinal Health 110 LLC | $275 |
| Janssen Scientific Affairs, LLC | $53.40 |
| Compensation for services other than consulting (speaking, faculty) | $4,235 |
|---|---|
| Consulting Fee | $3,090 |
| Food and Beverage | $53.40 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sobi, Inc Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) Gamifant · Hematology | $4,235 |
| Regeneron Pharmaceuticals, Inc. Nov 21, 2025 | Consulting Fee | $1,662 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee | $1,153 |
| Cardinal Health 110 LLC Jan 9, 2025 | Consulting Fee | $275 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $402,772 in research payments for these studies, mostly to the institutions running them.
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Beigene, Ltd. · Active, not recruiting · NCT06073821 - A Modular Phase I and II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects w…
AstraZeneca Pharmaceuticals LP - A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.